Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Edward Sausville

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Anatomy

Disorders

Procedures

Antitumor Drug Screening Assays

Living Beings

Physiology

Concepts & Ideas

Drug Dose-Response Relationship

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Sausville Edward A
Mitochondrial function as an emerging 'target of interest' for cancer treatment.
Borgman Mark P; Ray Abhijit; Kolhatkar Rohit B; Sausville Edward A; Burger Angelika M; Ghandehari Hamidreza
Targetable HPMA copolymer-aminohexylgeldanamycin conjugates for prostate cancer therapy.
Zhao Merry Y; Auerbach Aaron; D'Costa Anisha M; Rapoport Aaron P; Burger Angelika M; Sausville Edward A; Stass Sanford A; Jiang Feng; Sands Amy M; Aguilera Nadine; Zhao X Frank
Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Edward Sausville (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Sausville Edward A
Mitochondrial function as an emerging 'target of interest' for cancer treatment.
Current opinion in investigational drugs (London, England : 2000) 2009;10(6):523-5.
2009: Borgman Mark P; Ray Abhijit; Kolhatkar Rohit B; Sausville Edward A; Burger Angelika M; Ghandehari Hamidreza
Targetable HPMA copolymer-aminohexylgeldanamycin conjugates for prostate cancer therapy.
Pharmaceutical research 2009;26(6):1407-18.
2009: Zhao Merry Y; Auerbach Aaron; D'Costa Anisha M; Rapoport Aaron P; Burger Angelika M; Sausville Edward A; Stass Sanford A; Jiang Feng; Sands Amy M; Aguilera Nadine; Zhao X Frank
Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(5):1708-20.
2009: Shiozawa Ken; Nakanishi Takeo; Tan Ming; Fang Hong-Bin; Wang Wen-chyi; Edelman Martin J; Carlton David; Gojo Ivana; Sausville Edward A; Ross Douglas D
Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(5):1698-707.
2008: Fang Hong-Bin; Ross Douglas D; Sausville Edward; Tan Ming
Experimental design and interaction analysis of combination studies of drugs with log-linear dose responses.
Statistics in medicine 2008;27(16):3071-83.
2007: Strome Scott E; Sausville Edward A; Mann Dean
A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects.
The oncologist 2007;12(9):1084-95.
2007: Gojo Ivana; Jiemjit Anchalee; Trepel Jane B; Sparreboom Alex; Figg William D; Rollins Sandra; Tidwell Michael L; Greer Jacqueline; Chung Eun Joo; Lee Min-Jung; Gore Steven D; Sausville Edward A; Zwiebel James; Karp Judith E
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.
Blood 2007;109(7):2781-90.
2007: Le Son B; Hailer M Katie; Buhrow Sarah; Wang Qi; Flatten Karen; Pediaditakis Peter; Bible Keith C; Lewis Lionel D; Sausville Edward A; Pang Yuan-Ping; Ames Matthew M; Lemasters John J; Holmuhamedov Ekhson L; Kaufmann Scott H
Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity.
The Journal of biological chemistry 2007;282(12):8860-72.
2006: Mukhopadhyay Indranil; Sausville Edward A; Doroshow James H; Roy Krishnendu K
Molecular mechanism of adaphostin-mediated G1 arrest in prostate cancer (PC-3) cells: signaling events mediated by hepatocyte growth factor receptor, c-Met, and p38 MAPK pathways.
The Journal of biological chemistry 2006;281(49):37330-44.
2006: Acharya Milin R; Karp Judith E; Sausville Edward A; Hwang Kyunghwa; Ryan Qin; Gojo Ivana; Venitz Jurgen; Figg William D; Sparreboom Alex
Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer.
Investigational new drugs 2006;24(5):367-75.
2006: Sausville Edward A
Respecting cancer drug transportability: a basis for successful lead selection.
Journal of the National Cancer Institute 2006;98(16):1098-9.
2006: Sodhi Akrit; Chaisuparat Risa; Hu Jiadi; Ramsdell Amanda K; Manning Brendan D; Sausville Edward A; Sawai Earl T; Molinolo Alfredo; Gutkind J Silvio; Montaner Silvia
The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor.
Cancer cell 2006;10(2):133-43.
2006: Brantley Eileen; Antony Smitha; Kohlhagen Glenda; Meng Linghua; Agama Keli; Stinson Sherman F; Sausville Edward A; Pommier Yves
Anti-tumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces single-strand breaks and DNA-protein cross-links in sensitive MCF-7 breast cancer cells.
Cancer chemotherapy and pharmacology 2006;58(1):62-72.
2006: Sausville Edward A; Burger Angelika M
Contributions of human tumor xenografts to anticancer drug development.
Cancer research 2006;66(7):3351-4, discussion 3354.
2006: Wallqvist Anders; Connelly John; Sausville Edward A; Covell David G; Monks Anne
Differential gene expression as a potential classifier of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole-sensitive and -insensitive cell lines.
Molecular pharmacology 2006;69(3):737-48.
2006: Chandra Joya; Tracy Jeannette; Loegering David; Flatten Karen; Verstovsek Srdan; Beran Miloslav; Gorre Mercedes; Estrov Zeev; Donato Nicholas; Talpaz Moshe; Sawyers Charles; Bhalla Kapil; Karp Judith; Sausville Edward; Kaufmann Scott H
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.
Blood 2006;107(6):2501-6.
2006: Badros Ashraf; Weikel Dianna; Salama Andrew; Goloubeva Olga; Schneider Abraham; Rapoport Aaron; Fenton Robert; Gahres Natalie; Sausville Edward; Ord Robert; Meiller Timothy
Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(6):945-52.
2006: Acharya Milin R; Sparreboom Alex; Sausville Edward A; Conley Barbara A; Doroshow James H; Venitz Jurgen; Figg William D
Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor.
Cancer chemotherapy and pharmacology 2006;57(3):275-81.
2006: Kolonin Mikhail G; Bover Laura; Sun Jessica; Zurita Amado J; Do Kim-Anh; Lahdenranta Johanna; Cardó-Vila Marina; Giordano Ricardo J; Jaalouk Diana E; Ozawa Michael G; Moya Catherine A; Souza Glauco R; Staquicini Fernanda I; Kunyiasu Akihiko; Scudiero Dominic A; Holbeck Susan L; Sausville Edward A; Arap Wadih; Pasqualini Renata
Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries.
Cancer research 2006;66(1):34-40.
2006: Le S B; Holmuhamedov E L; Narayanan V L; Sausville E A; Kaufmann S H
Adaphostin and other anticancer drugs quench the fluorescence of mitochondrial potential probes.
Cell death and differentiation 2006;13(1):151-9.
2005: Van Waes Carter; Chang Angela A; Lebowitz Peter F; Druzgal Colleen H; Chen Zhong; Elsayed Yusri A; Sunwoo John B; Rudy Susan F; Morris John C; Mitchell James B; Camphausen Kevin; Gius David; Adams Julian; Sausville Edward A; Conley Barbara A
Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.
International journal of radiation oncology, biology, physics 2005;63(5):1400-12.
2005: Glaze Elizabeth R; Lambert Amy L; Smith Adaline C; Page John G; Johnson William D; McCormick David L; Brown Alan P; Levine Barry S; Covey Joseph M; Egorin Merrill J; Eiseman Julie L; Holleran Julianne L; Sausville Edward A; Tomaszewski Joseph E
Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance.
Cancer chemotherapy and pharmacology 2005;56(6):637-47.
2005: Decker Shannon; Sausville Edward A
Preclinical modeling of combination treatments: fantasy or requirement?
Annals of the New York Academy of Sciences 2005;1059():61-9.
2005: Amornphimoltham Panomwat; Patel Vyomesh; Sodhi Akrit; Nikitakis Nikolaos G; Sauk John J; Sausville Edward A; Molinolo Alfredo A; Gutkind J Silvio
Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Cancer research 2005;65(21):9953-61.
2005: Hose Curtis; Kaur Gurmeet; Sausville Edward A; Monks Anne
Transcriptional profiling identifies altered intracellular labile iron homeostasis as a contributing factor to the toxicity of adaphostin: decreased vascular endothelial growth factor secretion is independent of hypoxia-inducible factor-1 regulation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(17):6370-81.
2005: Jing Yongkui; Hellinger Nella; Xia Lijuan; Monks Anne; Sausville Edward A; Zelent Arthur; Waxman Samuel
Benzodithiophenes induce differentiation and apoptosis in human leukemia cells.
Cancer research 2005;65(17):7847-55.
2005: Shen Yuehai; Xie Qian; Norberg Monica; Sausville Edward; Woude George Vande; Wenkert David
Geldanamycin derivative inhibition of HGF/SF-mediated Met tyrosine kinase receptor-dependent urokinase-plasminogen activation.
Bioorganic & medicinal chemistry 2005;13(16):4960-71.
2005: Smith Victoria; Sausville Edward A; Camalier Richard F; Fiebig Heinz-Herbert; Burger Angelika M
Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
Cancer chemotherapy and pharmacology 2005;56(2):126-37.
2005: Hollingshead Melinda; Alley Michael; Burger Angelika M; Borgel Suzanne; Pacula-Cox Christine; Fiebig Heinz-Herbert; Sausville Edward A
In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative.
Cancer chemotherapy and pharmacology 2005;56(2):115-25.
2005: Fandy Tamer E; Shankar Sharmila; Ross Douglas D; Sausville Edward; Srivastava Rakesh K
Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma.
Neoplasia (New York, N.Y.) 2005;7(7):646-57.
2005: Meng Ling-hua; Kohlhagen Glenda; Liao Zhi-yong; Antony Smitha; Sausville Edward; Pommier Yves
DNA-protein cross-links and replication-dependent histone H2AX phosphorylation induced by aminoflavone (NSC 686288), a novel anticancer agent active against human breast cancer cells.
Cancer research 2005;65(12):5337-43.
2005: Sausville Edward A; Carducci Michael A
Making bad cells go good: the promise of epigenetic therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(17):3875-6.
2005: Ryan Qin C; Headlee Donna; Acharya Milin; Sparreboom Alex; Trepel Jane B; Ye Joseph; Figg William D; Hwang Kyunghwa; Chung Eun Joo; Murgo Anthony; Melillo Giovanni; Elsayed Yusri; Monga Manish; Kalnitskiy Mikhail; Zwiebel James; Sausville Edward A
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(17):3912-22.
2005: Xie Qian; Gao Chong-Feng; Shinomiya Nariyoshi; Sausville Edward; Hay Rick; Gustafson Margaret; Shen Yuehai; Wenkert David; Vande Woude George F
Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion.
Oncogene 2005;24(23):3697-707.
2005: Fuse Eiichi; Kuwabara Takashi; Sparreboom Alex; Sausville Edward A; Figg William D
Review of UCN-01 development: a lesson in the importance of clinical pharmacology.
Journal of clinical pharmacology 2005;45(4):394-403.
2005: Tudor Gabriela; Alley Mike; Nelson Christopher M; Huang Ruili; Covell David G; Gutierrez Peter; Sausville Edward A
Cytotoxicity of RH1: NAD(P)H:quinone acceptor oxidoreductase (NQO1)-independent oxidative stress and apoptosis induction.
Anti-cancer drugs 2005;16(4):381-91.
2005: McGrath Connor F; Pattabiraman Nagarajan; Kellogg Glen E; Lemcke Thomas; Kunick Conrad; Sausville Edward A; Zaharevitz Daniel W; Gussio Rick
Homology model of the CDK1/cyclin B complex.
Journal of biomolecular structure & dynamics 2005;22(5):493-502.
2005: Sausville Edward A
Indifferently pursued or unowned drugs: who should lead where companies do not tread?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(9):1796-8.
2005: Kaur Gurmeet; Narayanan Ven L; Risbood Prabhakar A; Hollingshead Melinda G; Stinson Sherman F; Varma Ravi K; Sausville Edward A
Synthesis, structure-activity relationship, and p210(bcr-abl) protein tyrosine kinase activity of novel AG 957 analogs.
Bioorganic & medicinal chemistry 2005;13(5):1749-61.
2005: Shanafelt Tait D; Lee Yean K; Bone Nancy D; Strege Ann K; Narayanan Ven L; Sausville Edward A; Geyer Susan M; Kaufmann Scott H; Kay Neil E
Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine.
Blood 2005;105(5):2099-106.
2005: Moreau Pascale; Holbeck Susan; Prudhomme Michelle; Sausville Edward A
Cytotoxicities of three rebeccamycin derivatives in the National Cancer Institute screening of 60 human tumor cell lines.
Anti-cancer drugs 2005;16(2):145-50.
2005: Brantley Eileen; Patel Vyomesh; Stinson Sherman F; Trapani Valentina; Hose Curtis D; Ciolino Henry P; Yeh Grace C; Gutkind J Silvio; Sausville Edward A; Loaiza-Pérez Andrea I
The antitumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces NF-kappaB activity in drug-sensitive MCF-7 cells.
Anti-cancer drugs 2005;16(2):137-43.
2005: Bhonde Mandar R; Hanski Marie-Luise; Magrini Roberta; Moorthy Dhatchana; Müller Antje; Sausville Edward A; Kohno Kimitoshi; Wiegand Peter; Daniel Peter T; Zeitz Martin; Hanski Christoph
The broad-range cyclin-dependent kinase inhibitor UCN-01 induces apoptosis in colon carcinoma cells through transcriptional suppression of the Bcl-x(L) protein.
Oncogene 2005;24(1):148-56.
2005: Chung Eun Joo; Lee Sunmin; Sausville Edward A; Ryan Qin; Karp Judith E; Gojo Ivana; Telford William G; Lee Min-Jung; Kong Hye Sik; Trepel Jane B
Histone deacetylase inhibitor pharmacodynamic analysis by multiparameter flow cytometry.
Annals of clinical and laboratory science 2005;35(4):397-406.
2005: Sausville Edward A
Cell cycle regulatory kinase modulators: interim progress and issues.
Current topics in medicinal chemistry 2005;5(12):1109-17.
2004: Shailubhai Kunwar; Dheer Surendra; Picker Donald; Kaur Gurmeet; Sausville Edward A; Jacob Gary S
Atiprimod is an inhibitor of cancer cell proliferation and angiogenesis.
Journal of experimental therapeutics & oncology 2004;4(4):267-79.
2004: Brantley Eileen; Trapani Valentina; Alley Michael C; Hose Curtis D; Bradshaw Tracey D; Stevens Malcolm F G; Sausville Edward A; Stinson Sherman F
Fluorinated 2-(4-amino-3-methylphenyl)benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human cancer cells.
Drug metabolism and disposition: the biological fate of chemicals 2004;32(12):1392-401.
2004: Sausville E A
Geldanamycin analogs.
Journal of chemotherapy (Florence, Italy) 2004;16 Suppl 4():68-9.
2004: Sausville E A
Target selection issues in drug discovery and development.
Journal of chemotherapy (Florence, Italy) 2004;16 Suppl 4():16-8.
2004: Gitler Miriam S; Sausville Edward A; Hollingshead Melinda; Shoemaker Robert
In vivo models for experimental therapeutics relevant to human cancer.
Cancer research 2004;64(22):8478-80.
2004: Sausville Edward A; Holbeck Susan L
Transcription profiling of gene expression in drug discovery and development: the NCI experience.
European journal of cancer (Oxford, England : 1990) 2004;40(17):2544-9.
2004: Kondapaka Sudhir B; Zarnowski Maryjane; Yver Dena R; Sausville Edward A; Cushman Samuel W
7-hydroxystaurosporine (UCN-01) inhibition of Akt Thr308 but not Ser473 phosphorylation: a basis for decreased insulin-stimulated glucose transport.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(21):7192-8.
2004: Sparreboom Alex; Chen Huachen; Acharya Milin R; Senderowicz Adrian M; Messmann Richard A; Kuwabara Takashi; Venzon David J; Murgo Anthony J; Headlee Donna; Sausville Edward A; Figg William D
Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(20):6840-6.
2004: Svingen Phyllis A; Loegering David; Rodriquez Joe; Meng Xue Wei; Mesner Peter W; Holbeck Susan; Monks Anne; Krajewski Stan; Scudiero Dominic A; Sausville Edward A; Reed John C; Lazebnik Yuri A; Kaufmann Scott H
Components of the cell death machine and drug sensitivity of the National Cancer Institute Cell Line Panel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(20):6807-20.
2004: Sausville Edward A
Optimizing target selection and development strategy in cancer treatment: the next wave.
Current medicinal chemistry. Anti-cancer agents 2004;4(5):445-7.
2004: Alley Michael C; Hollingshead Melinda G; Pacula-Cox Christine M; Waud William R; Hartley John A; Howard Philip W; Gregson Stephen J; Thurston David E; Sausville Edward A
SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations.
Cancer research 2004;64(18):6700-6.
2004: Hartley John A; Spanswick Victoria J; Brooks Natalie; Clingen Peter H; McHugh Peter J; Hochhauser Daniel; Pedley R Barbara; Kelland Lloyd R; Alley Michael C; Schultz Robert; Hollingshead Melinda G; Schweikart Karen M; Tomaszewski Joseph E; Sausville Edward A; Gregson Stephen J; Howard Philip W; Thurston David E
SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
Cancer research 2004;64(18):6693-9.
2004: Sausville Edward A
Versipelostatin: unfolding an unsweetened death.
Journal of the National Cancer Institute 2004;96(17):1266-7.
2004: Dasmahapatra Girija P; Didolkar Parijat; Alley Michael C; Ghosh Somiranjan; Sausville Edward A; Roy Krishnendu K
In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(15):5242-52.
2004: Kaur Gurmeet; Belotti Dorina; Burger Angelika M; Fisher-Nielson Kirsten; Borsotti Patrizia; Riccardi Elena; Thillainathan Jagada; Hollingshead Melinda; Sausville Edward A; Giavazzi Raffaella
Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(14):4813-21.
2004: Adams Brian K; Ferstl Eva M; Davis Matthew C; Herold Marike; Kurtkaya Serdar; Camalier Richard F; Hollingshead Melinda G; Kaur Gurmeet; Sausville Edward A; Rickles Frederick R; Snyder James P; Liotta Dennis C; Shoji Mamoru
Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents.
Bioorganic & medicinal chemistry 2004;12(14):3871-83.
2004: Amornphimoltham Panomwat; Sriuranpong Virote; Patel Vyomesh; Benavides Fernando; Conti Claudio J; Sauk John; Sausville Edward A; Molinolo Alfredo A; Gutkind J Silvio
Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 1):4029-37.
2004: Loaiza-Pérez Andrea I; Kenney Susan; Boswell Jamie; Hollingshead Melinda; Alley Michael C; Hose Curtis; Ciolino Henry P; Yeh Grace C; Trepel Jane B; Vistica David T; Sausville Edward A
Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells.
Molecular cancer therapeutics 2004;3(6):715-25.
2004: Hwang Kyunghwa; Acharya Milin R; Sausville Edward A; Zhai Suoping; Woo Eunhee W; Venitz Jürgen; Figg William D; Sparreboom Alex
Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;804(2):289-94.
2004: Sausville Edward A
Genes in the service of therapeutic index: progress for virus-directed enzyme prodrug therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(9):1535-7.
2004: Hollingshead M G; Bonomi C A; Borgel S D; Carter J P; Shoemaker R; Melillo G; Sausville E A
A potential role for imaging technology in anticancer efficacy evaluations.
European journal of cancer (Oxford, England : 1990) 2004;40(6):890-8.
2004: Decker S; Hollingshead M; Bonomi C A; Carter J P; Sausville E A
The hollow fibre model in cancer drug screening: the NCI experience.
European journal of cancer (Oxford, England : 1990) 2004;40(6):821-6.
2004: Burger Angelika M; Fiebig Heinz-Herbert; Stinson Sherman F; Sausville Edward A
17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models.
Anti-cancer drugs 2004;15(4):377-87.
2004: Sodhi Akrit; Montaner Silvia; Patel Vyomesh; Gómez-Román José Javier; Li Yi; Sausville Edward A; Sawai Earl T; Gutkind J Silvio
Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(14):4821-6.
2004: Loaiza-Pérez A I; Kenney S; Boswell J; Hollingshead M; Hose C; Linehan W M; Worrell R; Rubinstein L; Sausville E A; Vistica D T
Sensitivity of renal cell carcinoma to aminoflavone: role of CYP1A1.
The Journal of urology 2004;171(4):1688-97.
2004: Sausville Edward A
Aurora kinases dawn as cancer drug targets.
Nature medicine 2004;10(3):234-5.
2004: Sausville Edward
Protein chaperones as anticancer therapy targets.
Clinical advances in hematology & oncology : H&O 2004;2(2):92-3.
2004: Bani Maria Rosa; Nicoletti Maria Ines; Alkharouf Nawal W; Ghilardi Carmen; Petersen David; Erba Eugenio; Sausville Edward A; Liu Edison T; Giavazzi Raffaella
Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts.
Molecular cancer therapeutics 2004;3(2):111-21.
2004: Yu Chunrong; Rahmani Mohamed; Almenara Jorge; Sausville Edward A; Dent Paul; Grant Steven
Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK- and AKT-dependent process.
Oncogene 2004;23(7):1364-76.
2004: Schimmer Aaron D; Welsh Kate; Pinilla Clemencia; Wang Zhiliang; Krajewska Maryla; Bonneau Marie-Josee; Pedersen Irene M; Kitada Shinichi; Scott Fiona L; Bailly-Maitre Beatrice; Glinsky Gennadi; Scudiero Dominick; Sausville Edward; Salvesen Guy; Nefzi Adel; Ostresh John M; Houghten Richard A; Reed John C
Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity.
Cancer cell 2004;5(1):25-35.
2004: Panchal Rekha G; Hermone Ann R; Nguyen Tam Luong; Wong Thiang Yian; Schwarzenbacher Robert; Schmidt James; Lane Douglas; McGrath Connor; Turk Benjamin E; Burnett James; Aman M Javad; Little Stephen; Sausville Edward A; Zaharevitz Daniel W; Cantley Lewis C; Liddington Robert C; Gussio Rick; Bavari Sina
Identification of small molecule inhibitors of anthrax lethal factor.
Nature structural & molecular biology 2004;11(1):67-72.
2003: Hose Curtis D; Hollingshead Melinda; Sausville Edward A; Monks Anne
Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5-fluoro-benzothiazole: a potential surrogate marker for patient sensitivity.
Molecular cancer therapeutics 2003;2(12):1265-72.
2003: Chandra Joya; Hackbarth Jennifer; Le Son; Loegering David; Bone Nancy; Bruzek Laura M; Narayanan Ven L; Adjei Alex A; Kay Neil E; Tefferi Ayalew; Karp Judith E; Sausville Edward A; Kaufmann Scott H
Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells.
Blood 2003;102(13):4512-9.
2003: Sharkey Robert M; Sausville Edward A; Goldenberg David M
Meeting report on the Ninth Conference on Cancer Therapy with Antibodies and Immunoconjugates.
Cancer research 2003;63(22):8069-71.
2003: Wallqvist Anders; Rabow Alfred A; Shoemaker Robert H; Sausville Edward A; Covell David G
Linking the growth inhibition response from the National Cancer Institute's anticancer screen to gene expression levels and other molecular target data.
Bioinformatics (Oxford, England) 2003;19(17):2212-24.
2003: Kondapaka Sudhir B; Singh Sheo S; Dasmahapatra Girija P; Sausville Edward A; Roy Krishnendu K
Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation.
Molecular cancer therapeutics 2003;2(11):1093-103.
2003: Sausville Edward A; Tomaszewski Joseph E; Ivy Percy
Clinical development of 17-allylamino, 17-demethoxygeldanamycin.
Current cancer drug targets 2003;3(5):377-83.
2003: Rudek Michelle A; Bauer Kenneth S; Lush Richard M; Stinson Sherman F; Senderowicz Adrian M; Headlee Donna J; Arbuck Susan G; Cox Michael C; Murgo Anthony J; Sausville Edward A; Figg William D
Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.
The Annals of pharmacotherapy 2003;37(10):1369-74.
2003: Burnett James C; Schmidt James J; Stafford Robert G; Panchal Rekha G; Nguyen Tam L; Hermone Ann R; Vennerstrom Jonathan L; McGrath Connor F; Lane Douglas J; Sausville Edward A; Zaharevitz Daniel W; Gussio Rick; Bavari Sina
Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity.
Biochemical and biophysical research communications 2003;310(1):84-93.
2003: Avramis Ioannis A; Laug Walter E; Sausville Edward A; Avramis Vassilios I
Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Cancer chemotherapy and pharmacology 2003;52(4):307-18.
2003: Gitler Miriam S; Monks Anne; Sausville Edward A
Preclinical models for defining efficacy of drug combinations: mapping the road to the clinic.
Molecular cancer therapeutics 2003;2(9):929-32.
2003: Nishizuka Satoshi; Chen Sing-Tsung; Gwadry Fuad G; Alexander Jes; Major Sylvia M; Scherf Uwe; Reinhold William C; Waltham Mark; Charboneau Lu; Young Lynn; Bussey Kimberly J; Kim Sohyoung; Lababidi Samir; Lee Jae K; Pittaluga Stefania; Scudiero Dominic A; Sausville Edward A; Munson Peter J; Petricoin Emmanuel F; Liotta Lance A; Hewitt Stephen M; Raffeld Mark; Weinstein John N
Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling.
Cancer research 2003;63(17):5243-50.
2003: Glover Constance J; Hite Karen; DeLosh Renee; Scudiero Dominic A; Fivash Matthew J; Smith Lindsey R; Fisher Robert J; Wu Jia Wei; Shi Yigong; Kipp Rachael A; McLendon George L; Sausville Edward A; Shoemaker Robert H
A high-throughput screen for identification of molecular mimics of Smac/DIABLO utilizing a fluorescence polarization assay.
Analytical biochemistry 2003;320(2):157-69.
2003: Jia Wentao; Yu Chunrong; Rahmani Mohamed; Krystal Geoffrey; Sausville Edward A; Dent Paul; Grant Steven
Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways.
Blood 2003;102(5):1824-32.
2003: Rybak Susanna M; Sanovich Elena; Hollingshead Melinda G; Borgel Suzanne D; Newton Dianne L; Melillo Giovanni; Kong Dehe; Kaur Gurmeet; Sausville Edward A
"Vasocrine" formation of tumor cell-lined vascular spaces: implications for rational design of antiangiogenic therapies.
Cancer research 2003;63(11):2812-9.
2003: Sausville Edward A
Imatinib for chronic myelogenous leukaemia: a 9 or 24 carat gold standard?
Lancet 2003;361(9367):1400-1.
2003: Sausville Edward A
Is another bcr-abl inhibitor needed for chronic myelogenous leukemia?
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(4):1233-4.
2003: Dancey Janet; Sausville Edward A
Issues and progress with protein kinase inhibitors for cancer treatment.
Nature reviews. Drug discovery 2003;2(4):296-313.
2003: Tudor Gabriela; Gutierrez Peter; Aguilera-Gutierrez Angelica; Sausville Edward A
Cytotoxicity and apoptosis of benzoquinones: redox cycling, cytochrome c release, and BAD protein expression.
Biochemical pharmacology 2003;65(7):1061-75.
2003: Monks Anne; Harris Erik; Hose Curtis; Connelly John; Sausville Edward A
Genotoxic profiling of MCF-7 breast cancer cell line elucidates gene expression modifications underlying toxicity of the anticancer drug 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole.
Molecular pharmacology 2003;63(3):766-72.
2003: Trapani V; Patel V; Leong C-O; Ciolino H P; Yeh G C; Hose C; Trepel J B; Stevens M F G; Sausville E A; Loaiza-Pérez A I
DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells.
British journal of cancer 2003;88(4):599-605.
2003: Messmann Richard A; Ullmann Claudio Dansky; Lahusen Tyler; Kalehua Audrey; Wasfy Jason; Melillo Giovanni; Ding Ivan; Headlee Donna; Figg William D; Sausville Edward A; Senderowicz Adrian M
Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(2):562-70.
2003: Zhai Suoping; Sausville Edward A; Senderowicz Adrian M; Ando Yuichi; Headlee Donna; Messmann Richard A; Arbuck Susan; Murgo Anthony J; Melillo Giovanni; Fuse Eiichi; Figg William D
Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms.
Anti-cancer drugs 2003;14(2):125-35.
2003: Sausville Edward; Verweij Jaap
Highlights from the EORTC-NCI-AACR 2002 meeting: molecular targets and cancer therapeutics.
Clinical advances in hematology & oncology : H&O 2003;1(1):22-3.
2003: Sausville Edward A
Cyclin-dependent kinase modulators studied at the NCI: pre-clinical and clinical studies.
Current medicinal chemistry. Anti-cancer agents 2003;3(1):47-56.
2003: Panasci L; Stinson S F; Melnychuk D; Sandor V; Miller W H; Batist G; Patenaude F; Bangash N; Panarello L; Alaoui-Jamali M; Sausville E
SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(2):232-40.
2003: Zhou Bin-Bing S; Sausville Edward A
Drug discovery targeting Chk1 and Chk2 kinases.
Progress in cell cycle research 2003;5():413-21.
2003: Sausville Edward A; Elsayed Yusri; Monga Manish; Kim George
Signal transduction--directed cancer treatments.
Annual review of pharmacology and toxicology 2003;43():199-231.
2002: Newman David J; Cragg Gordon M; Holbeck Susan; Sausville Edward A
Natural products and derivatives as leads to cell cycle pathway targets in cancer chemotherapy.
Current cancer drug targets 2002;2(4):279-308.
2002: Avramis Ioannis A; Christodoulopoulos Garyfallia; Suzuki Atsushi; Laug Walter E; Gonzalez-Gomez Ignacio; McNamara George; Sausville Edward A; Avramis Vassilios I
In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines.
Cancer chemotherapy and pharmacology 2002;50(6):479-89.
2002: Patel Vyomesh; Lahusen Tyler; Leethanakul Chidchanok; Igishi Tadashi; Kremer Marcus; Quintanilla-Martinez Leticia; Ensley John F; Sausville Edward A; Gutkind J Silvio; Senderowicz Adrian M
Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(11):3549-60.
2002: Sausville Edward A
International Society for Oncodevelopmental Biology and Medicine - XXXth Meeting.
IDrugs : the investigational drugs journal 2002;5(10):958-60.
2002: Tan Antoinette R; Headlee Donna; Messmann Richard; Sausville Edward A; Arbuck Susan G; Murgo Anthony J; Melillo Giovanni; Zhai Suoping; Figg William D; Swain Sandra M; Senderowicz Adrian M
Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(19):4074-82.
2002: Tamminga Carol A; Nemeroff Charles B; Blakely Randy D; Brady Linda; Carter Cameron S; Davis Kenneth L; Dingledine Raymond; Gorman Jack M; Grigoriadis Dimitri E; Henderson David C; B Innis Robert B; Killen John; Laughren Thomas P; McDonald William M; M Murphy Greer M; Paul Steven M; Rudorfer Matthew V; Sausville Edward; Schatzberg Alan F; Scolnick Edward M; Suppes Trisha
Developing novel treatments for mood disorders: accelerating discovery.
Biological psychiatry 2002;52(6):589-609.
2002: Zhai Suoping; Sausville Edward; Figg William D
A high-performance liquid chromatography method using ultraviolet detection for the quantitation of flavopiridol from human plasma.
Biomedical chromatography : BMC 2002;16(6):379-82.
2002: Rapisarda Annamaria; Uranchimeg Badarch; Scudiero Dominic A; Selby Mike; Sausville Edward A; Shoemaker Robert H; Melillo Giovanni
Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway.
Cancer research 2002;62(15):4316-24.
2002: Xu Zhiyuan; Chen Zhong-Ping; Malapetsa Areti; Alaoui-Jamali Moulay; Bergeron Josée; Monks Anne; Myers Timothy G; Mohr Gérard; Sausville Edward A; Scudiero Dominic A; Aloyz Raquel; Panasci Lawrence C
DNA repair protein levels vis-à-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program.
Anti-cancer drugs 2002;13(5):511-9.
2002: Zhai Suoping; Senderowicz Adrian M; Sausville Edward A; Figg William D
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
The Annals of pharmacotherapy 2002;36(5):905-11.
2002: Monga M; Sausville E A
Developmental therapeutics program at the NCI: molecular target and drug discovery process.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(4):520-6.
2002: Bradshaw T D; Chua M-S; Browne H L; Trapani V; Sausville E A; Stevens M F G
In vitro evaluation of amino acid prodrugs of novel antitumour 2-(4-amino-3-methylphenyl)benzothiazoles.
British journal of cancer 2002;86(8):1348-54.
2002: Wallqvist Anders; Rabow Alfred A; Shoemaker Robert H; Sausville Edward A; Covell David G
Establishing connections between microarray expression data and chemotherapeutic cancer pharmacology.
Molecular cancer therapeutics 2002;1(5):311-20.
2002: Chen Zhong-ping; Malapetsa Areti; Monks Anne; Myers Timothy G; Mohr Gérard; Sausville Edward A; Scudiero Dominic A; Panasci Lawrence C
Nucleotide excision repair protein levels vis-à-vis anticancer drug resistance in 60 human tumor cell lines.
Ai zheng = Aizheng = Chinese journal of cancer 2002;21(3):233-9.
2002: Sawyers Charles L; Sausville Edward A
Overview: the art of cancer drug screening: molecular target versus milieu-based screens.
Current opinion in investigational drugs (London, England : 2000) 2002;3(3):478-81.
2002: Shoemaker Robert H; Scudiero Dominic A; Melillo Giovanni; Currens Michael J; Monks Anne P; Rabow Alfred A; Covell David G; Sausville Edward A
Application of high-throughput, molecular-targeted screening to anticancer drug discovery.
Current topics in medicinal chemistry 2002;2(3):229-46.
2002: Patel Vyomesh; Lahusen Tyler; Sy Terence; Sausville Edward A; Gutkind J Sivio; Senderowicz Adrian M
Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest.
Cancer research 2002;62(5):1401-9.
2002: Bradshaw Tracey D; Bibby Michael C; Double John A; Fichtner Iduna; Cooper Patricia A; Alley Michael C; Donohue Susan; Stinson Sherman F; Tomaszewjski Joseph E; Sausville Edward A; Stevens Malcolm F G
Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles.
Molecular cancer therapeutics 2002;1(4):239-46.
2002: Thambi Paul; Sausville Edward A
STI571 (imatinib mesylate): the tale of a targeted therapy.
Anti-cancer drugs 2002;13(2):111-4.
2002: Rabow Alfred A; Shoemaker Robert H; Sausville Edward A; Covell David G
Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities.
Journal of medicinal chemistry 2002;45(4):818-40.
2002: Park Seok Hee; Lee Sae Ra; Kim Byung Chul; Cho Eun Ah; Patel Sejal P; Kang Hee-Bum; Sausville Edward A; Nakanishi Osamu; Trepel Jane B; Lee Byoung Ick; Kim Seong-Jin
Transcriptional regulation of the transforming growth factor beta type II receptor gene by histone acetyltransferase and deacetylase is mediated by NF-Y in human breast cancer cells.
The Journal of biological chemistry 2002;277(7):5168-74.
2002: Mow Benjamin M F; Chandra Joya; Svingen Phyllis A; Hallgren Christopher G; Weisberg Ellen; Kottke Timothy J; Narayanan Ven L; Litzow Mark R; Griffin James D; Sausville Edward A; Tefferi Ayalew; Kaufmann Scott H
Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.
Blood 2002;99(2):664-71.
2002: Loaiza-Pérez Andrea I; Trapani Valentina; Hose Curtis; Singh Sheo S; Trepel Jane B; Stevens Malcolm F G; Bradshaw Tracey D; Sausville Edward A
Aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to antitumor agent 2-(4-amino-3-methylphenyl) benzothiazole.
Molecular pharmacology 2002;61(1):13-9.
2002: Sausville Edward A
Complexities in the development of cyclin-dependent kinase inhibitor drugs.
Trends in molecular medicine 2002;8(4 Suppl):S32-7.
2002: Pandeya Surendra N; Yogeeswari Perumal; Sausville Edward A; Mauger Anthony B; Narayanan Ven L
Synthesis and antitumour evaluation of 4-bromophenyl semicarbazones.
Arzneimittel-Forschung 2002;52(2):103-8.
2001: Roy K K; Sausville E A
Early development of cyclin dependent kinase modulators.
Current pharmaceutical design 2001;7(16):1669-87.
2001: Searle F; Gac-Breton S; Keane R; Dimitrijevic S; Brocchini S; Sausville E A; Duncan R
N-(2-hydroxypropyl)methacrylamide copolymer-6-(3-aminopropyl)-ellipticine conjugates. Synthesis, in vitro, and preliminary in vivo evaluation.
Bioconjugate chemistry 2001;12(5):711-8.
2001: Woo E W; Messmann R; Sausville E A; Figg W D
Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-electrospray mass spectrometry.
Journal of chromatography. B, Biomedical sciences and applications 2001;759(2):247-57.
2001: Sausville E A
Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Commentary re: P. Münster et al., Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin. Cancer Res., 7: 2228-2236, 2001.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2155-8.
2001: Sausville E A
Scientific summation and future goals.
Journal of controlled release : official journal of the Controlled Release Society 2001;74(1-3):1-6.
2001: Dudkin L; Dilling M B; Cheshire P J; Harwood F C; Hollingshead M; Arbuck S G; Travis R; Sausville E A; Houghton P J
Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(6):1758-64.
2001: Byrd J C; Shinn C; Willis C R; Flinn I W; Lehman T; Sausville E; Lucas D; Grever M R
UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism.
Experimental hematology 2001;29(6):703-8.
2001: Johnson J I; Decker S; Zaharevitz D; Rubinstein L V; Venditti J M; Schepartz S; Kalyandrug S; Christian M; Arbuck S; Hollingshead M; Sausville E A
Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.
British journal of cancer 2001;84(10):1424-31.
2001: Sunwoo J B; Chen Z; Dong G; Yeh N; Crowl Bancroft C; Sausville E; Adams J; Elliott P; Van Waes C
Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(5):1419-28.
2001: Sausville E A; Arbuck S G; Messmann R; Headlee D; Bauer K S; Lush R M; Murgo A; Figg W D; Lahusen T; Jaken S; Jing X; Roberge M; Fuse E; Kuwabara T; Senderowicz A M
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(8):2319-33.
2001: Hagenauer B; Salamon A; Thalhammer T; Kunert O; Haslinger E; Klingler P; Senderowicz A M; Sausville E A; Jäger W
In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: involvement of UDP-glucuronosyltransferases 1A1 and 1A9.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(4 Pt 1):407-14.
2001: Yu L J; Matias J; Scudiero D A; Hite K M; Monks A; Sausville E A; Waxman D J
P450 enzyme expression patterns in the NCI human tumor cell line panel.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(3):304-12.
2001: Bai R; Verdier-Pinard P; Gangwar S; Stessman C C; McClure K J; Sausville E A; Pettit G R; Bates R B; Hamel E
Dolastatin 11, a marine depsipeptide, arrests cells at cytokinesis and induces hyperpolymerization of purified actin.
Molecular pharmacology 2001;59(3):462-9.
2001: Sausville E
11th NCI-EORTC-AACR: New therapeutic targets, signal transduction and angiogenesis.
IDrugs : the investigational drugs journal 2001;4(2):148-53.
2001: Kahn M E; Senderowicz A; Sausville E A; Barrett K E
Possible mechanisms of diarrheal side effects associated with the use of a novel chemotherapeutic agent, flavopiridol.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(2):343-9.
2001: Schindler J; Sausville E; Messmann R; Uhr J W; Vitetta E S
The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(2):255-8.
2001: Lee B I; Park S H; Kim J W; Sausville E A; Kim H T; Nakanishi O; Trepel J B; Kim S J
MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells.
Cancer research 2001;61(3):931-4.
2001: Newton D L; Kaur G; Rhim J S; Sausville E A; Rybak S M
RNA damage and inhibition of neoplastic endothelial cell growth: effects of human and amphibian ribonucleases.
Radiation research 2001;155(1 Pt 2):171-174.
2001: Sausville E A
The challenge of pathway and environment-mediated drug resistance.
Cancer metastasis reviews 2001;20(1-2):117-22.
2001: Elsayed Y A; Sausville E A
Selected novel anticancer treatments targeting cell signaling proteins.
The oncologist 2001;6(6):517-37.
2001: Arbuck S G; Dancey J; Pluda J M; Grochow L; Murgo A J; Ivy P; Wright J; Blaylock B; Via L E; Sausville E A
New targets for cancer chemotherapy.
Cancer chemotherapy and biological response modifiers 2001;19():237-88.
2001: Lam L T; Pickeral O K; Peng A C; Rosenwald A; Hurt E M; Giltnane J M; Averett L M; Zhao H; Davis R E; Sathyamoorthy M; Wahl L M; Harris E D; Mikovits J A; Monks A P; Hollingshead M G; Sausville E A; Staudt L M
Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol.
Genome biology 2001;2(10):RESEARCH0041.
2001: Sausville E A; Shoemaker R H
Role of the National Cancer Institute in acquired immunodeficiency syndrome-related drug discovery.
Journal of the National Cancer Institute. Monographs 2001;(28):55-7.
2000: Sausville E A
Overview. Cancer drug discovery: pathway promise or covalent certainty for drug effect--quo vadis?
Current opinion in investigational drugs (London, England : 2000) 2000;1(4):511-3.
2000: Sausville E A; Johnson J I
Molecules for the millennium: how will they look? New drug discovery year 2000.
British journal of cancer 2000;83(11):1401-4.
2000: Sausville E A
Dragons 'round the fleece again: STI571 versus alpha1 acid glycoprotein.
Journal of the National Cancer Institute 2000;92(20):1626-7.
2000: Mandler R; Wu C; Sausville E A; Roettinger A J; Newman D J; Ho D K; King C R; Yang D; Lippman M E; Landolfi N F; Dadachova E; Brechbiel M W; Waldmann T A
Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines.
Journal of the National Cancer Institute 2000;92(19):1573-81.
2000: Leost M; Schultz C; Link A; Wu Y Z; Biernat J; Mandelkow E M; Bibb J A; Snyder G L; Greengard P; Zaharevitz D W; Gussio R; Senderowicz A M; Sausville E A; Kunick C; Meijer L
Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25.
European journal of biochemistry / FEBS 2000;267(19):5983-94.
2000: Chua M S; Kashiyama E; Bradshaw T D; Stinson S F; Brantley E; Sausville E A; Stevens M F
Role of Cyp1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells.
Cancer research 2000;60(18):5196-203.
2000: Sandor V; Senderowicz A; Mertins S; Sackett D; Sausville E; Blagosklonny M V; Bates S E
P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228.
British journal of cancer 2000;83(6):817-25.
2000: Chao S H; Fujinaga K; Marion J E; Taube R; Sausville E A; Senderowicz A M; Peterlin B M; Price D H
Flavopiridol inhibits P-TEFb and blocks HIV-1 replication.
The Journal of biological chemistry 2000;275(37):28345-8.
2000: Bauer K S; Lush R M; Rudek M A; Shih C; Sausville E; Figg W D
A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva.
Biomedical chromatography : BMC 2000;14(5):338-43.
2000: Sandor V; Robbins A R; Robey R; Myers T; Sausville E; Bates S E; Sackett D L
FR901228 causes mitotic arrest but does not alter microtubule polymerization.
Anti-cancer drugs 2000;11(6):445-54.
2000: Arris C E; Boyle F T; Calvert A H; Curtin N J; Endicott J A; Garman E F; Gibson A E; Golding B T; Grant S; Griffin R J; Jewsbury P; Johnson L N; Lawrie A M; Newell D R; Noble M E; Sausville E A; Schultz R; Yu W
Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.
Journal of medicinal chemistry 2000;43(15):2797-804.
2000: Sausville E A; Johnson J; Alley M; Zaharevitz D; Senderowicz A M
Inhibition of CDKs as a therapeutic modality.
Annals of the New York Academy of Sciences 2000;910():207-21; discussion 221-2.
2000: Tudor G; Aguilera A; Halverson D O; Laing N D; Sausville E A
Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-xL protein levels.
Cell death and differentiation 2000;7(6):574-86.
2000: Sausville E A
Use of immunotoxins in the treatment of lymphoma.
Cancer journal (Sudbury, Mass.) 2000;6(3):135-8.
2000: Monks A; Harris E D; Vaigro-Wolff A; Hose C D; Connelly J W; Sausville E A
UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines.
Investigational new drugs 2000;18(2):95-107.
2000: Kamishohara M; Kenney S; Domergue R; Vistica D T; Sausville E A
Selective accumulation of the endoplasmic reticulum-Golgi intermediate compartment induced by the antitumor drug KRN5500.
Experimental cell research 2000;256(2):468-79.
2000: Keskin O; Bahar I; Jernigan R L; Beutler J A; Shoemaker R H; Sausville E A; Covell D G
Characterization of anticancer agents by their growth inhibitory activity and relationships to mechanism of action and structure.
Anti-cancer drug design 2000;15(2):79-98.
2000: Messmann R A; Vitetta E S; Headlee D; Senderowicz A M; Figg W D; Schindler J; Michiel D F; Creekmore S; Steinberg S M; Kohler D; Jaffe E S; Stetler-Stevenson M; Chen H; Ghetie V; Sausville E A
A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1302-13.
2000: Kunick C; Schultz C; Lemcke T; Zaharevitz D W; Gussio R; Jalluri R K; Sausville E A; Leost M; Meijer L
2-Substituted paullones: CDK1/cyclin B-inhibiting property and in vitro antiproliferative activity.
Bioorganic & medicinal chemistry letters 2000;10(6):567-9.
2000: Scherf U; Ross D T; Waltham M; Smith L H; Lee J K; Tanabe L; Kohn K W; Reinhold W C; Myers T G; Andrews D T; Scudiero D A; Eisen M B; Sausville E A; Pommier Y; Botstein D; Brown P O; Weinstein J N
A gene expression database for the molecular pharmacology of cancer.
Nature genetics 2000;24(3):236-44.
2000: Senderowicz A M; Sausville E A
Preclinical and clinical development of cyclin-dependent kinase modulators.
Journal of the National Cancer Institute 2000;92(5):376-87.
2000: Gussio R; Zaharevitz D W; McGrath C F; Pattabiraman N; Kellogg G E; Schultz C; Link A; Kunick C; Leost M; Meijer L; Sausville E A
Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition.
Anti-cancer drug design 2000;15(1):53-66.
2000: Sausville E A
Protein kinase antagonists: interim challenges and issues.
Anti-cancer drug design 2000;15(1):1-2.
2000: Wilson W H; Sorbara L; Figg W D; Mont E K; Sausville E; Warren K E; Balis F M; Bauer K; Raffeld M; Senderowicz A M; Monks A
Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigm.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(2):415-21.
2000: Frankel A E; Kreitman R J; Sausville E A
Targeted toxins.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(2):326-34.
2000: Graves P R; Yu L; Schwarz J K; Gales J; Sausville E A; O'Connor P M; Piwnica-Worms H
The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01.
The Journal of biological chemistry 2000;275(8):5600-5.
2000: Webb C P; Hose C D; Koochekpour S; Jeffers M; Oskarsson M; Sausville E; Monks A; Vande Woude G F
The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.
Cancer research 2000;60(2):342-9.
2000: Svingen P A; Tefferi A; Kottke T J; Kaur G; Narayanan V L; Sausville E A; Kaufmann S H
Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(1):237-49.
1999: Sausville E A; Feigal E
Evolving approaches to cancer drug discovery and development at the National Cancer Institute, USA.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(11):1287-91.
1999: Melillo G; Sausville E A; Cloud K; Lahusen T; Varesio L; Senderowicz A M
Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes.
Cancer research 1999;59(21):5433-7.
1999: Kashiyama E; Hutchinson I; Chua M S; Stinson S F; Phillips L R; Kaur G; Sausville E A; Bradshaw T D; Westwell A D; Stevens M F
Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
Journal of medicinal chemistry 1999;42(20):4172-84.
1999: Carlson B; Lahusen T; Singh S; Loaiza-Perez A; Worland P J; Pestell R; Albanese C; Sausville E A; Senderowicz A M
Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol.
Cancer research 1999;59(18):4634-41.
1999: Nieves-Neira W; Rivera M I; Kohlhagen G; Hursey M L; Pourquier P; Sausville E A; Pommier Y
DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells.
Molecular pharmacology 1999;56(3):478-84.
1999: Schultz C; Link A; Leost M; Zaharevitz D W; Gussio R; Sausville E A; Meijer L; Kunick C
Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity.
Journal of medicinal chemistry 1999;42(15):2909-19.
1999: Schnier J B; Kaur G; Kaiser A; Stinson S F; Sausville E A; Gardner J; Nishi K; Bradbury E M; Senderowicz A M
Identification of cytosolic aldehyde dehydrogenase 1 from non-small cell lung carcinomas as a flavopiridol-binding protein.
FEBS letters 1999;454(1-2):100-4.
1999: Adams J; Palombella V J; Sausville E A; Johnson J; Destree A; Lazarus D D; Maas J; Pien C S; Prakash S; Elliott P J
Proteasome inhibitors: a novel class of potent and effective antitumor agents.
Cancer research 1999;59(11):2615-22.
1999: Zaharevitz D W; Gussio R; Leost M; Senderowicz A M; Lahusen T; Kunick C; Meijer L; Sausville E A
Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases.
Cancer research 1999;59(11):2566-9.
1999: Rivera M I; Stinson S F; Vistica D T; Jorden J L; Kenney S; Sausville E A
Selective toxicity of the tricyclic thiophene NSC 652287 in renal carcinoma cell lines: differential accumulation and metabolism.
Biochemical pharmacology 1999;57(11):1283-95.
1999: Sausville E A; Zaharevitz D; Gussio R; Meijer L; Louarn-Leost M; Kunick C; Schultz R; Lahusen T; Headlee D; Stinson S; Arbuck S G; Senderowicz A
Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target.
Pharmacology & therapeutics 1999;82(2-3):285-92.
1999: Losiewicz M D; Kaur G; Sausville E A
Different early effets of tyrphostin AG957 and geldanamycins on mitogen-activated protein kinase and p120cbl phosphorylation in anti CD-3-stimulated T-lymphoblasts.
Biochemical pharmacology 1999;57(3):281-9.
1999: Sausville E A
A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: a promising path for progress emerges.
Journal of the National Cancer Institute 1999;91(2):102-3.
1999: Senderowicz A M; Reid R; Headlee D; Abornathy T; Horti J; Lush R M; Reed E; Figg W D; Sausville E A
A phase II trial of gallium nitrate in patients with androgen-metastatic prostate cancer.
Urologia internationalis 1999;63(2):120-5.
1998: Tamm I; Wang Y; Sausville E; Scudiero D A; Vigna N; Oltersdorf T; Reed J C
IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs.
Cancer research 1998;58(23):5315-20.
1998: Yu L; Orlandi L; Wang P; Orr M S; Senderowicz A M; Sausville E A; Silvestrini R; Watanabe N; Piwnica-Worms H; O'Connor P M
UCN-01 abrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase.
The Journal of biological chemistry 1998;273(50):33455-64.
1998: Byrd J C; Shinn C; Waselenko J K; Fuchs E J; Lehman T A; Nguyen P L; Flinn I W; Diehl L F; Sausville E; Grever M R
Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.
Blood 1998;92(10):3804-16.
1998: Patel V; Senderowicz A M; Pinto D; Igishi T; Raffeld M; Quintanilla-Martinez L; Ensley J F; Sausville E A; Gutkind J S
Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
The Journal of clinical investigation 1998;102(9):1674-81.
1998: Senderowicz A M; Headlee D; Stinson S F; Lush R M; Kalil N; Villalba L; Hill K; Steinberg S M; Figg W D; Tompkins A; Arbuck S G; Sausville E A
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(9):2986-99.
1998: Fuse E; Tanii H; Kurata N; Kobayashi H; Shimada Y; Tamura T; Sasaki Y; Tanigawara Y; Lush R D; Headlee D; Figg W D; Arbuck S G; Senderowicz A M; Sausville E A; Akinaga S; Kuwabara T; Kobayashi S
Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein.
Cancer research 1998;58(15):3248-53.
1998: Scudiero D A; Monks A; Sausville E A
Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen.
Journal of the National Cancer Institute 1998;90(11):862.
1998: Arguello F; Alexander M; Sterry J A; Tudor G; Smith E M; Kalavar N T; Greene J F; Koss W; Morgan C D; Stinson S F; Siford T J; Alvord W G; Klabansky R L; Sausville E A
Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts.
Blood 1998;91(7):2482-90.
1998: Conley B A; Egorin M J; Tait N; Rosen D M; Sausville E A; Dover G; Fram R J; Van Echo D A
Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(3):629-34.
1998: Byrd J C; Rai K R; Sausville E A; Grever M R
Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goals.
Seminars in oncology 1998;25(1):65-74.
1998: Dawson N; Figg W D; Brawley O W; Bergan R; Cooper M R; Senderowicz A; Headlee D; Steinberg S M; Sutherland M; Patronas N; Sausville E; Linehan W M; Reed E; Sartor O
Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(1):37-44.
1998: Arguello F; Alexander M A; Greene J F; Stinson S F; Jorden J L; Smith E M; Kalavar N T; Alvord W G; Klabansky R L; Sausville E A
Preclinical evaluation of 9-chloro-2-methylellipticinium acetate alone and in combination with conventional anticancer drugs for the treatment of human brain tumor xenografts.
Journal of cancer research and clinical oncology 1998;124(1):19-26.
1998: Parker B W; Kaur G; Nieves-Neira W; Taimi M; Kohlhagen G; Shimizu T; Losiewicz M D; Pommier Y; Sausville E A; Senderowicz A M
Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol.
Blood 1998;91(2):458-65.
1998: Kitada S; Krajewska M; Zhang X; Scudiero D; Zapata J M; Wang H G; Shabaik A; Tudor G; Krajewski S; Myers T G; Johnson G S; Sausville E A; Reed J C
Expression and location of pro-apoptotic Bcl-2 family protein BAD in normal human tissues and tumor cell lines.
The American journal of pathology 1998;152(1):51-61.
1998: Takeuchi H; Ara G; Sausville E A; Teicher B
Jasplakinolide: interaction with radiation and hyperthermia in human prostate carcinoma and Lewis lung carcinoma.
Cancer chemotherapy and pharmacology 1998;42(6):491-6.
1998: Sausville E A; Lush R D; Headlee D; Smith A C; Figg W D; Arbuck S G; Senderowicz A M; Fuse E; Tanii H; Kuwabara T; Kobayashi S
Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models.
Cancer chemotherapy and pharmacology 1998;42 Suppl():S54-9.
1998: Engert A; Sausville E A; Vitetta E
The emerging role of ricin A-chain immunotoxins in leukemia and lymphoma.
Current topics in microbiology and immunology 1998;234():13-33.
1998: Jäger W; Zembsch B; Wolschann P; Pittenauer E; Senderowicz A M; Sausville E A; Sedlacek H H; Graf J; Thalhammer T
Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver.
Life sciences 1998;62(20):1861-73.
1997: Sausville E A
Correspondence re: G. Palumbo et al., the tyrphostin AG17 induces apoptosis and inhibition of cdk2 activity in a lymphoma cell line that overexpresses bcl-2. Cancer Res., 57: 2434-2439, 1997.
Cancer research 1997;57(24):5610.
1997: Monks A; Scudiero D A; Johnson G S; Paull K D; Sausville E A
The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets.
Anti-cancer drug design 1997;12(7):533-41.
1997: O'Connor P M; Jackman J; Bae I; Myers T G; Fan S; Mutoh M; Scudiero D A; Monks A; Sausville E A; Weinstein J N; Friend S; Fornace A J; Kohn K W
Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.
Cancer research 1997;57(19):4285-300.
1997: Marcantonio D; Panasci L C; Hollingshead M G; Alley M C; Camalier R F; Sausville E A; Dykes D J; Carter C A; Malspeis L
2-Chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts.
Cancer research 1997;57(18):3895-8.
1997: Grenert J P; Sullivan W P; Fadden P; Haystead T A; Clark J; Mimnaugh E; Krutzsch H; Ochel H J; Schulte T W; Sausville E; Neckers L M; Toft D O
The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation.
The Journal of biological chemistry 1997;272(38):23843-50.
1997: Senderowicz A M; Vitetta E; Headlee D; Ghetie V; Uhr J W; Figg W D; Lush R M; Stetler-Stevenson M; Kershaw G; Kingma D W; Jaffe E S; Sausville E A
Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin.
Annals of internal medicine 1997;126(11):882-5.
1997: Dawson N A; Figg W D; Cooper M R; Sartor O; Bergan R C; Senderowicz A M; Steinberg S M; Tompkins A; Weinberger B; Sausville E A; Reed E; Myers C E
Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(4):1470-7.
1997: Christian M C; Pluda J M; Ho P T; Arbuck S G; Murgo A J; Sausville E A
Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute.
Seminars in oncology 1997;24(2):219-40.
1997: Freije J M; Lawrence J A; Hollingshead M G; De la Rosa A; Narayanan V; Grever M; Sausville E A; Paull K; Steeg P S
Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human breast carcinoma and melanoma cell lines.
Nature medicine 1997;3(4):395-401.
1997: Burger A M; Kaur G; Hollingshead M; Fischer R T; Nagashima K; Malspeis L; Duncan K L; Sausville E A
Antiproliferative activity in vitro and in vivo of the spicamycin analogue KRN5500 with altered glycoprotein expression in vitro.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(3):455-63.
1997: Myers T G; Anderson N L; Waltham M; Li G; Buolamwini J K; Scudiero D A; Paull K D; Sausville E A; Weinstein J N
A protein expression database for the molecular pharmacology of cancer.
Electrophoresis 1997;18(3-4):647-53.
1997: Rice W G; Turpin J A; Huang M; Clanton D; Buckheit R W; Covell D G; Wallqvist A; McDonnell N B; DeGuzman R N; Summers M F; Zalkow L; Bader J P; Haugwitz R D; Sausville E A
Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein.
Nature medicine 1997;3(3):341-5.
1997: Drees M; Dengler W A; Roth T; Labonte H; Mayo J; Malspeis L; Grever M; Sausville E A; Fiebig H H
Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(2):273-9.
1997: Weinstein J N; Myers T G; O'Connor P M; Friend S H; Fornace A J; Kohn K W; Fojo T; Bates S E; Rubinstein L V; Anderson N L; Buolamwini J K; van Osdol W W; Monks A P; Scudiero D A; Sausville E A; Zaharevitz D W; Bunow B; Viswanadhan V N; Johnson G S; Wittes R E; Paull K D
An information-intensive approach to the molecular pharmacology of cancer.
Science (New York, N.Y.) 1997;275(5298):343-9.
1996: Kaur G; Sausville E A
Altered physical state of p210bcr-abl in tyrphostin AG957-treated K562 cells.
Anti-cancer drugs 1996;7(8):815-24.
1996: Duncan K L; Duncan M D; Alley M C; Sausville E A
Cucurbitacin E-induced disruption of the actin and vimentin cytoskeleton in prostate carcinoma cells.
Biochemical pharmacology 1996;52(10):1553-60.
1996: Baluna R; Sausville E A; Stone M J; Stetler-Stevenson M A; Uhr J W; Vitetta E S
Decreases in levels of serum fibronectin predict the severity of vascular leak syndrome in patients treated with ricin A chain-containing immunotoxins.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(10):1705-12.
1996: Turpin J A; Terpening S J; Schaeffer C A; Yu G; Glover C J; Felsted R L; Sausville E A; Rice W G
Inhibitors of human immunodeficiency virus type 1 zinc fingers prevent normal processing of gag precursors and result in the release of noninfectious virus particles.
Journal of virology 1996;70(9):6180-9.
1996: Stone M J; Sausville E A; Fay J W; Headlee D; Collins R H; Figg W D; Stetler-Stevenson M; Jain V; Jaffe E S; Solomon D; Lush R M; Senderowicz A; Ghetie V; Schindler J; Uhr J W; Vitetta E S
A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma.
Blood 1996;88(4):1188-97.
1996: Yasuda S U; Sausville E A; Hutchins J B; Kennedy T; Woosley R L
Amiodarone-induced lymphocyte toxicity and mitochondrial function.
Journal of cardiovascular pharmacology 1996;28(1):94-100.
1996: Carlson B A; Dubay M M; Sausville E A; Brizuela L; Worland P J
Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Cancer research 1996;56(13):2973-8.
1996: Wang Q; Fan S; Eastman A; Worland P J; Sausville E A; O'Connor P M
UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.
Journal of the National Cancer Institute 1996;88(14):956-65.
1996: De Azevedo W F; Mueller-Dieckmann H J; Schulze-Gahmen U; Worland P J; Sausville E; Kim S H
Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(7):2735-40.
1996: Sausville E A; Duncan K L; Senderowicz A; Plowman J; Randazzo P A; Kahn R; Malspeis L; Grever M R
Antiproliferative effect in vitro and antitumor activity in vivo of brefeldin A.
The cancer journal from Scientific American 1996;2(1):52-8.
1996: Fathi Z; Way J W; Corjay M H; Viallet J; Sausville E A; Battey J F
Bombesin receptor structure and expression in human lung carcinoma cell lines.
Journal of cellular biochemistry. Supplement 1996;24():237-46.
1996: Viallet J; Sausville E A
Involvement of signal transduction pathways in lung cancer biology.
Journal of cellular biochemistry. Supplement 1996;24():228-36.
1995: Foss F M; Sausville E A
Prognosis and staging of cutaneous T-cell lymphoma.
Hematology/oncology clinics of North America 1995;9(5):1011-9.
1995: Dawson N A; Cooper M R; Figg W D; Headlee D J; Thibault A; Bergan R C; Steinberg S M; Sausville E A; Myers C E; Sartor O
Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables.
Cancer 1995;76(3):453-62.
1995: Wang Q; Worland P J; Clark J L; Carlson B A; Sausville E A
Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1995;6(8):927-36.
1995: Burger A M; Kaur G; Alley M C; Supko J G; Malspeis L; Grever M R; Sausville E A
Tyrphostin AG17, [(3,5-Di-tert-butyl-4-hydroxybenzylidene)- malononitrile], inhibits cell growth by disrupting mitochondria.
Cancer research 1995;55(13):2794-9.
1995: Takahashi N; Sausville E A; Breitman T R
N-(4-hydroxyphenyl)retinamide (Fenretinide) in combination with retinoic acid enhances differentiation and retinoylation of proteins.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(6):637-42.
1995: Sausville E A; Headlee D; Stetler-Stevenson M; Jaffe E S; Solomon D; Figg W D; Herdt J; Kopp W C; Rager H; Steinberg S M
Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study.
Blood 1995;85(12):3457-65.
1995: Senderowicz A M; Kaur G; Sainz E; Laing C; Inman W D; Rodríguez J; Crews P; Malspeis L; Grever M R; Sausville E A
Jasplakinolide's inhibition of the growth of prostate carcinoma cells in vitro with disruption of the actin cytoskeleton.
Journal of the National Cancer Institute 1995;87(1):46-51.
1994: McCarty M J; Vukelja S J; Sausville E A; Perry J J; James W D; Jaffe E S; Weiss R B
Lymphomatoid papulosis associated with Ki-1-positive anaplastic large cell lymphoma. A report of two cases and a review of the literature.
Cancer 1994;74(11):3051-8.
1994: Kuchnio M; Sausville E A; Jaffe E S; Greiner T; Foss F M; McClanahan J; Fukushima P; Stetler-Stevenson M A
Flow cytometric detection of neoplastic T cells in patients with mycosis fungoides based on levels of T-cell receptor expression.
American journal of clinical pathology 1994;102(6):856-60.
1994: Cohen R; Jaffe E S; Stetler-Stevenson M A; Sausville E A; DeNigris E C; Woodworth T; Foss F M
Bilateral adrenal hemorrhage and adrenal insufficiency in a patient with lymphomatous adrenal infiltration following administration of a fusion toxin (DAB486 interleukin-2).
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;16(3):229-33.
1994: Seynaeve C M; Kazanietz M G; Blumberg P M; Sausville E A; Worland P J
Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue.
Molecular pharmacology 1994;45(6):1207-14.
1994: Losiewicz M D; Carlson B A; Kaur G; Sausville E A; Worland P J
Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275.
Biochemical and biophysical research communications 1994;201(2):589-95.
1994: Bubb M R; Senderowicz A M; Sausville E A; Duncan K L; Korn E D
Jasplakinolide, a cytotoxic natural product, induces actin polymerization and competitively inhibits the binding of phalloidin to F-actin.
The Journal of biological chemistry 1994;269(21):14869-71.
1994: Kaur G; Gazit A; Levitzki A; Stowe E; Cooney D A; Sausville E A
Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia.
Anti-cancer drugs 1994;5(2):213-22.
1994: Foss F M; Koc Y; Stetler-Stevenson M A; Nguyen D T; O'Brien M C; Turner R; Sausville E A
Costimulation of cutaneous T-cell lymphoma cells by interleukin-7 and interleukin-2: potential autocrine or paracrine effectors in the Sézary syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(2):326-35.
1993: Worland P J; Kaur G; Stetler-Stevenson M; Sebers S; Sartor O; Sausville E A
Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity.
Biochemical pharmacology 1993;46(10):1831-40.
1993: Danilenko M; Worland P; Carlson B; Sausville E A; Sharoni Y
Selective effects of mastoparan analogs: separation of G-protein-directed and membrane-perturbing activities.
Biochemical and biophysical research communications 1993;196(3):1296-302.
1993: Graham S J; Sharpe R W; Steinberg S M; Cotelingam J D; Sausville E A; Foss F M
Prognostic implications of a bone marrow histopathologic classification system in mycosis fungoides and the Sézary syndrome.
Cancer 1993;72(3):726-34.
1993: Dobrzanski D; Sharoni Y; Wada E; Battey J; Sausville E
Neuromedin-B receptor transfected BALB/3T3 cells: signal transduction and effects of ectopic receptor expression on cell growth.
Regulatory peptides 1993;45(3):341-52.
1993: Seynaeve C M; Stetler-Stevenson M; Sebers S; Kaur G; Sausville E A; Worland P J
Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells.
Cancer research 1993;53(9):2081-6.
1993: Fathi Z; Corjay M H; Shapira H; Wada E; Benya R; Jensen R; Viallet J; Sausville E A; Battey J F
BRS-3: a novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells.
The Journal of biological chemistry 1993;268(8):5979-84.
1993: Laborda J; Sausville E A; Hoffman T; Notario V
dlk, a putative mammalian homeotic gene differentially expressed in small cell lung carcinoma and neuroendocrine tumor cell line.
The Journal of biological chemistry 1993;268(6):3817-20.
1992: Kaur G; Stetler-Stevenson M; Sebers S; Worland P; Sedlacek H; Myers C; Czech J; Naik R; Sausville E
Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275.
Journal of the National Cancer Institute 1992;84(22):1736-40.
1992: Sausville E A
T-cell leukemia-lymphoma and mycosis fungoides.
Current opinion in oncology 1992;4(5):829-39.
1992: Lynch J W; Linoilla I; Sausville E A; Steinberg S M; Ghosh B C; Nguyen D T; Schechter G P; Fischmann A B; Ihde D C; Stocker J L
Prognostic implications of evaluation for lymph node involvement by T-cell antigen receptor gene rearrangement in mycosis fungoides.
Blood 1992;79(12):3293-9.
1992: Kaur G; Viallet J; Laborda J; Blair O; Gazdar A F; Minna J D; Sausville E A
Growth inhibition by cholera toxin of human lung carcinoma cell lines: correlation with GM1 ganglioside expression.
Cancer research 1992;52(12):3340-6.
1991: Atienza D M; Vigersky R J; Lack E E; Carriaga M; Rusnock E J; Tsou E; Cerrone F; Kattah J G; Sausville E A
Prolactin-producing pituitary carcinoma with pulmonary metastases.
Cancer 1991;68(7):1605-10.
1991: Corjay M H; Dobrzanski D J; Way J M; Viallet J; Shapira H; Worland P; Sausville E A; Battey J F
Two distinct bombesin receptor subtypes are expressed and functional in human lung carcinoma cells.
The Journal of biological chemistry 1991;266(28):18771-9.
1991: Mulshine J L; Carrasquillo J A; Weinstein J N; Keenan A M; Reynolds J C; Herdt J; Bunn P A; Sausville E; Eddy J; Cotelingam J D
Direct intralymphatic injection of radiolabeled 111In-T101 in patients with cutaneous T-cell lymphoma.
Cancer research 1991;51(2):688-95.
1990: Viallet J; Sharoni Y; Frucht H; Jensen R T; Minna J D; Sausville E A
Cholera toxin inhibits signal transduction by several mitogens and the in vitro growth of human small-cell lung cancer.
The Journal of clinical investigation 1990;86(6):1904-12.
1990: Sharoni Y; Viallet J; Trepel J B; Sausville E A
Effect of guanine and adenine nucleotides on bombesin-stimulated phospholipase C activity in membranes from Swiss 3T3 and small cell lung carcinoma cells.
Cancer research 1990;50(17):5257-62.
1990: Bhatia K G; Cherney B W; Huppi K; Magrath I T; Cossman J; Sausville E; Barriga F; Johnson B; Gause B; Bonney G
A deletion linked to a poly(ADP-ribose) polymerase gene on chromosome 13q33-qter occurs frequently in the normal black population as well as in multiple tumor DNA.
Cancer research 1990;50(17):5406-13.
1990: Kohn E C; Steis R G; Sausville E A; Veach S R; Stocker J L; Phelps R; Franco S; Longo D L; Bunn P A; Ihde D C
Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(1):155-60.
1990: Sausville E A; Trepel J B; Moyer J D
Inhibitors of bombesin-stimulated intracellular signals: interruption of an autocrine pathway as a therapeutic strategy in small cell lung carcinoma.
Progress in clinical and biological research 1990;354A():193-207.
1989: Rosolen A; Nakanishi M; Poplack D G; Cole D; Quinones R; Reaman G; Trepel J B; Cotelingam J D; Sausville E A; Marti G E
Expression of interleukin-2 receptor beta subunit in hematopoietic malignancies.
Blood 1989;73(7):1968-72.
1989: Mulshine J L; Natale R B; Avis I; Treston A M; Kasprzyk P G; Nakanishi Y; Sausville E A; Trepel J B; Cuttitta F
Autocrine growth factors and lung cancer.
Cancer treatment and research 1989;45():107-22.
1988: Trepel J B; Moyer J D; Cuttitta F; Frucht H; Coy D H; Natale R B; Mulshine J L; Jensen R T; Sausville E A
A novel bombesin receptor antagonist inhibits autocrine signals in a small cell lung carcinoma cell line.
Biochemical and biophysical research communications 1988;156(3):1383-9.
1988: De Greve J; Battey J; Fedorko J; Birrer M; Evan G; Kaye F; Sausville E; Minna J
The human L-myc gene encodes multiple nuclear phosphoproteins from alternatively processed mRNAs.
Molecular and cellular biology 1988;8(10):4381-8.
1988: Trepel J B; Moyer J D; Heikkila R; Sausville E A
Modulation of bombesin-induced phosphatidylinositol hydrolysis in a small-cell lung-cancer cell line.
The Biochemical journal 1988;255(2):403-10.
1988: Sausville E A; Eddy J L; Makuch R W; Fischmann A B; Schechter G P; Matthews M; Glatstein E; Ihde D C; Kaye F; Veach S R
Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups.
Annals of internal medicine 1988;109(5):372-82.
1988: Markowitz S; Krystal G; Lebacq-Verheyden A M; Way J; Sausville E A; Battey J
Transcriptional activation and DNase I hypersensitive sites are associated with selective expression of the gastrin-releasing peptide gene.
The Journal of clinical investigation 1988;82(3):808-15.
1988: Krystal G; Birrer M; Way J; Nau M; Sausville E; Thompson C; Minna J; Battey J
Multiple mechanisms for transcriptional regulation of the myc gene family in small-cell lung cancer.
Molecular and cellular biology 1988;8(8):3373-81.
1988: Birrer M J; Segal S; DeGreve J S; Kaye F; Sausville E A; Minna J D
L-myc cooperates with ras to transform primary rat embryo fibroblasts.
Molecular and cellular biology 1988;8(6):2668-73.
1988: Colamonici O R; Quinones R; Rosolen A; Trepel J B; Sausville E; Phares J C; Gress R; Poplack D; Weber J; Schechter G P
The beta subunit of the interleukin-2 receptor mediates interleukin-2 induction of anti-CD3 redirected cytotoxic capability in large granular lymphocytes.
Blood 1988;71(3):825-8.
1988: Kaye F; Battey J; Nau M; Brooks B; Seifter E; De Greve J; Birrer M; Sausville E; Minna J
Structure and expression of the human L-myc gene reveal a complex pattern of alternative mRNA processing.
Molecular and cellular biology 1988;8(1):186-95.
1988: Minna J D; Cuttitta F; Battey J F; Mulshine J L; Linnoila I; Gazdar A F; Trepel J; Sausville E A
Gastrin-releasing peptide and other autocrine growth factors in lung cancer: pathogenetic and treatment implications.
Important advances in oncology 1988;():55-64.
1988: Sausville E A; Moyer J D; Heikkila R; Neckers L M; Trepel J B
A correlation of bombesin-responsiveness with myc-family gene expression in small cell lung carcinoma cell lines.
Annals of the New York Academy of Sciences 1988;547():310-21.
1987: Heikkila R; Trepel J B; Cuttitta F; Neckers L M; Sausville E A
Bombesin-related peptides induce calcium mobilization in a subset of human small cell lung cancer cell lines.
The Journal of biological chemistry 1987;262(34):16456-60.
1987: Veillette A; Foss F M; Sausville E A; Bolen J B; Rosen N
Expression of the lck tyrosine kinase gene in human colon carcinoma and other non-lymphoid human tumor cell lines.
Oncogene research 1987;1(4):357-74.
1987: Trepel J B; Colamonici O R; Kelly K; Schwab G; Watt R A; Sausville E A; Jaffe E S; Neckers L M
Transcriptional inactivation of c-myc and the transferrin receptor in dibutyryl cyclic AMP-treated HL-60 cells.
Molecular and cellular biology 1987;7(7):2644-8.
1987: Kaye F J; McBride O W; Battey J F; Gazdar A F; Sausville E A
Human creatine kinase-B complementary DNA. Nucleotide sequence, gene expression in lung cancer, and chromosomal assignment to two distinct loci.
The Journal of clinical investigation 1987;79(5):1412-20.
1987: Schechter G P; Sausville E A; Fischmann A B; Soehnlen F; Eddy J; Matthews M; Gazdar A; Guccion J; Munson D; Makuch R
Evaluation of circulating malignant cells provides prognostic information in cutaneous T cell lymphoma.
Blood 1987;69(3):841-9.
1987: Dmitrovsky E; Matthews M J; Bunn P A; Schechter G P; Makuch R W; Winkler C F; Eddy J; Sausville E A; Ihde D C
Cytologic transformation in cutaneous T cell lymphoma: a clinicopathologic entity associated with poor prognosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(2):208-15.
1986: Winkler C F; Sausville E A; Ihde D C; Fischmann A B; Schechter G P; Kumar P P; Nibhanupdi J R; Minna J D; Makuch R W; Eddy J L
Combined modality treatment of cutaneous T cell lymphoma: results of a 6-year follow-up.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(7):1094-100.
1986: Seifter E J; Sausville E A; Battey J
Comparison of amplified and unamplified c-myc gene structure and expression in human small cell lung carcinoma cell lines.
Cancer research 1986;46(4 Pt 2):2050-5.
1986: Sausville E A; Lebacq-Verheyden A M; Spindel E R; Cuttitta F; Gazdar A F; Battey J F
Expression of the gastrin-releasing peptide gene in human small cell lung cancer. Evidence for alternative processing resulting in three distinct mRNAs.
The Journal of biological chemistry 1986;261(5):2451-7.
1986: Nau M M; Brooks B J; Carney D N; Gazdar A F; Battey J F; Sausville E A; Minna J D
Human small-cell lung cancers show amplification and expression of the N-myc gene.
Proceedings of the National Academy of Sciences of the United States of America 1986;83(4):1092-6.
1986: Minna J D; Battey J F; Birrer M; Brooks B J; Cuttitta F; DeGreve J; Gazdar A F; Johnson B E; Nau M M; Sausville E A
Chromosomal deletion, gene amplification, alternative processing, and autocrine growth factor production in the pathogenesis of human lung cancer.
Princess Takamatsu symposia 1986;17():109-22.
1985: Sausville E A; Worsham G F; Matthews M J; Makuch R W; Fischmann A B; Schechter G P; Gazdar A F; Bunn P A
Histologic assessment of lymph nodes in mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma): clinical correlations and prognostic import of a new classification system.
Human pathology 1985;16(11):1098-109.
1985: Nau M M; Brooks B J; Battey J; Sausville E; Gazdar A F; Kirsch I R; McBride O W; Bertness V; Hollis G F; Minna J D
L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer.
Nature 1985;318(6041):69-73.
1985: Sausville E; Carney D; Battey J
The human vasopressin gene is linked to the oxytocin gene and is selectively expressed in a cultured lung cancer cell line.
The Journal of biological chemistry 1985;260(18):10236-41.
1978: Sausville E A; Horwitz S B
Inhibition of SV40 DNA synthesis by camptothecin and neocarzinostatin.
Molecular pharmacology 1978;14(6):1156-66.
1978: Sausville E A; Stein R W; Peisach J; Horwitz S B
Properties and products of the degradation of DNA by bleomycin and iron(II).
Biochemistry 1978;17(14):2746-54.
1978: Sausville E A; Peisach J; Horwitz S B
Effect of chelating agents and metal ions on the degradation of DNA by bleomycin.
Biochemistry 1978;17(14):2740-6.
1976: Sausville E A; Peisach J; Horwitz S B
A role for ferrous ion and oxygen in the degradation of DNA by bleomycin.
Biochemical and biophysical research communications 1976;73(3):814-22.
1975: Villanueva G B; Batt C W; Sausville E; Tortorelli V; Cubelli K; Brunner W
Changes in the exposure of tryptophyl and tyrosyl residues in thrombin due to diisopropylphosphorofluoridate and benzamidine inhibitions.
Biochemical and biophysical research communications 1975;67(1):359-65.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Edward Sausville

Research Profile (preview)

Chemicals & Drugs

Anatomy

Disorders

Procedures

Living Beings

Physiology

Concepts & Ideas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Edward Sausville (preview)

All Publications